Sharon Rosenzweig-Lipson, AgeneBio VP of Research and Development, Presents at the 9th Annual Neurodegeneration Drug Development Summit

AgeneBio Featured at Longevity Innovations and Neurodegeneration Company Showcase

HOPE4MCI Trial: First Trial Targeting Reduction of Hippocampal Overactivity to Treat Mild Cognitive Impairment due to Alzheimer’s Disease with AGB101